SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma informs about updates

20 Dec 2024 Evaluate
Mankind Pharma has informed that the Fund Raising Committee of Directors of the Company at its meeting held today December 20, 2024 approved the allotment of 1,19,04,761 Equity Shares of face value of ?1 each to the eligible Qualified Institutional Buyers at the issue price of ?2,520 per Equity Share, at a premium of ? 2519/- per Equity Share aggregating to ? 29,99,99,97,720 pursuant to the Issue. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from ? 40,06,62,138 consisting 40,06,62,138 Equity Shares to ? 41,25,66,899 consisting of 412566899 Equity Shares having face value of Re. 1 each. The new shares shall rank pari pasu with the existing shares. Further, it attached the list of allottees who have been allotted more than five percent of the Equity Shares offered in the Issue, marked as Annexure A. The Issue opened on December 16, 2024 and closed on December 19, 2024 and the same were intimated to the stock exchanges vide its letters dated December 16, 2024 and December 19, 2024 respectively. The information as required under Regulation 30 of SEBI Listing Regulations read with Schedule - III part- A to the SEBI Listing Regulations and SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, each as amended is enclosed.

The above information is a part of company’s filings submitted to BSE.

Mankind Pharma Share Price

2272.95 -18.90 (-0.82%)
24-Apr-2026 11:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1625.50
Dr. Reddys Lab 1318.65
Cipla 1285.05
Zydus Lifesciences 929.50
Lupin 2273.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×